• 医学文献
  • 知识库
  • 评价分析
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
  • 临床诊疗知识库
  • 中医药知识库
  • 机构
  • 作者
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

医学文献 >>
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
热搜词:
换一批

肾移植后发生尿路上皮肿瘤的患者转换西罗莫司治疗的临床观察

Clinical observation of conversion to sirolimus in the treatment of urothelial carcinoma following renal transplantation

摘要:

目的 观察肾移植后发生尿路上皮肿瘤的患者使用西罗莫司(SRL)联合低剂量钙调磷酸酶抑制剂(CNI)免疫抑制方案的有效性和安全性.方法 对15例肾移植后发生尿路上皮肿瘤的患者调整免疫抑制方案,采用SRL替代霉酚酸酯(或硫唑嘌呤).SRL的初始负荷剂量为2 mg,次日剂量为1 mg,之后根据SRL血药浓度调整维持剂量,使血药浓度维持在4~6μg/L;在其血药浓度稳定后将CNI减少至原用量的1/3.全部肿瘤患者均行手术治疗并辅以局部灌注化疗.转换SRL期间观察患者肿瘤的复发情况、移植肾功能及不良反应.结果 对15例患者随访2年中,9例肿瘤无复发;6例复发,其中2例复发2次,4例复发1次.在复发的患者中,4例肿瘤病理分级较转换SRL前降低,2例与转换前相同.所有复发的患者均再次行手术治疗.所有患者在使用SRL期间均未出现急性排斥反应,且其中11例患者肾功能指标较治疗前下降,4例肾功能保持稳定.转换治疗过程中出现高脂血症12例,不明原因发热4例,血小板减少3例,关节疼痛2例,所有不良反应经对症治疗后症状均有所好转.结论 肾移植后发生尿路上皮肿瘤的患者使用SRL联合低剂量CNI的免疫抑制方案是安全和有效的.

更多
abstracts:

Objective To evaluate the efficacy and safety of sirolimus combined with low dose calcineurin inhibitor to treat 15 renal allograft recipients with urothelial carcinoma. Methods The im-munosuppressive regimen was modulated in 15 recepients. MMF or Aza was replaced with sirolimus. The loading dose was 2 mg/d and the next dose was 1 mg/d. The sirolimus dosage was adjusted ac-cording to the blood level and the sustained blood level was 4~6 μg/L. In all the 15 cases the calci-neurin inhibitor was reduced to one third of the original dosage after the sirolimus blood level was sta-ble. Surgical treatment and intravesical instillation chemotherapy were carried out in all cases. During the treatment, the recurrence of the tumor, the allograft function and adverse effect were observed. Results Of the 15 cases, 9 cases had no tumor recurrence within 2 years. Two cases had tumor recur-rences twice and 4 cases once Among the recurrent cases, the tumol's pathology grade in 4 eases was degraded and 2 cases were identical after conversion. All recurrent patients had been treated with sur-gery again. There was no acute rejection observed during sirolimus treatment. The graft function of 11 cases was improved with a decrease of creatinine and 4 cases kept stabilization. There was hyperlipoi-demia in 12 cases, unknown fever in 4 cases, thrombocytopenia in 3 cases and arthralgia in 2 cases during conversion. All the adverse events were improved after treatment. Conclusion Among the re-nal allograft recipients with urothelial carcinoma, combined with low dose calcineurin inhibitor is an ef-fective and safe treatment regimen.

More
作者: 胡小鹏 [1] 马麟麟 [1] 王勇 [1] 尹航 [1] 王玮 [1] 杨晓勇 [1] 张小东 [1]
分类号: R6
栏目名称: 临床研究
DOI: 10.3760/cma.j.issn.0254-1785.2008.10.012
发布时间: 2008-12-17
  • 浏览:257
  • 下载:44

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

扩展文献

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷